Recently, T-DXd in recurrent or refractory NSCLC harboring HER2 mutations or protein overexpression showed better results with an ORR of 55%, an mPFS of 8.2 months, a median duration of response (mDOR) of 9.3 months and a mOS of 17.8 months in the mutant cohort [40]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.